Zantac
A Canada-wide class action alleges Zantac makers concealed cancer risks linked to ranitidine, seeking refunds and damages.
Opening soonOntario, QuebecDeadline: Pending court decisionEst. payout: Compensation pendingDeadline pending
About this settlement
The case concerns undisclosed cancer risks from ranitidine in Zantac products sold in Canada, with claims that manufacturers failed to warn consumers.
This class action targets manufacturers of Zantac and ranitidine generics for allegedly hiding cancer risks from consumers in Canada. The lawsuit seeks refunds, punitive damages, and other relief for those who purchased or ingested Zantac, which metabolizes into a probable carcinogen called NDMA.
Who qualifies
- Anyone in Canada who purchased or ingested Zantac or ranitidine products.
- Includes both over-the-counter and prescription ranitidine users.
- Residents of Canada, including Quebec and Ontario.
Compensation pending
Deadline Pending court decision